Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 274-282

  Groll, Andreas H ^a   Giri, Neelam ^a   Petraitis, Vidmantas ^a   Petraitiene, Ruta ^a   Candelario, Myrna ^a   Bacher, John S ^b   Piscitelli, Stephen C ^c   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; LIPID COMPOSITION; MENINGOENCEPHALITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA ALBICANS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; LIPIDS; MICROBIAL SENSITIVITY TESTS; RABBITS; TREATMENT OUTCOME;

EID: 0033943712     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315643     Document Type: Article

References (59)

1. 1. Salaki JS, Louria DB, Chmel H. Fungal and yeast infections of the central nervous system: a clinical review. Medicine (Baltimore) 1984; 63:108-32.
2. 2. Treseler CB, Sugar AM. Fungal meningitis. Infect Dis Clin North Am 1990; 4: 789-808.
3. 3. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
4. 4. Davis LE. Fungal infections of the central nervous system. Neurol Clin 1999; 17:761-81.
5. 5. Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 1984; 105: 616-22.
6. 6. Smego RA Jr, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984; 6: 791-801.
7. 7. Marina NM, Flynn PM, Rivera GK, Hughes WT. Candida tropicalis and Candida albicans fungemia in children with leukemia. Cancer 1991; 68: 594-9.
8. 8. Flynn PM, Marina NM, Rivera GK, Hughes WT. Candida tropicalis infections in children with leukemia. Leuk Lymphoma 1993; 10:369-76.
9. 9. Huttova M, Kralinsky K, Horn J, et al. Prospective study of nosocomial fungal meningitis in children: report of 10 cases. Scand J Infect Dis 1998; 30:485-7.
10. 10. Lee BE, Cheung PY, Robinson JL, Evanochko C, Robertson CM. Comparative study of mortality and morbidity in premature infants (birth weight, <1,250 g) with candidemia or candidal meningitis. Clin Infect Dis 1998; 27:559-65.
11. 11. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343-500.
12. 12. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 1992; 23:279-91.
13. 13. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22(Suppl 2):S133-44.
14. 14. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996; 9:512-31.
15. 15. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-18.
16. 16. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
17. 17. Walsh TJ, Bacher P, Pizzo PA. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab Anim Sci 1988; 38:467-71.
18. 18. Lee J, Allende M, Amantea M, et al. Pharmacokinetics and efficacy of amphotericin B lipid complex (ABLC) against chronic disseminated candidiasis in rabbits [abstract 579]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991.
19. 19. Allende MC, Lee JW, Francis P, et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38:518-22.
20. 20. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169: 356-68.
21. 21. Antifungal antibiotics. In: AHFS drug information. Bethesda, MD: American Society of Health System Pharmacists, 1999:74-85.
22. 22. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. Wayne, PA: NCCLS (document M27A), 1997.
23. 23. Walsh TJ, McEntee C, Dixon DM. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol 1987; 25:931-2.
24. 24. Brassine C, Laduron C, Coune A, et al. High-performance liquid Chromatographic determination of amphotericin B in human serum. J Chromatogr 1987; 419:401-7.
25. 25. Gibaldi M, Perrier D. Pharmacokinetics, 2d ed. New York: Marcel Dekker, 1982:455-9.
26. 26. Olson J, Satorius A, McAndrews B, Adler-Moore J. Treatment of systemic murine candidiasis with amphotericin B or different amphotericin B lipid formulations [abstract B11]. In: Program and abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:28.
27. 27. Clemons KV, Stevens DA. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998; 42:899-902.
28. 28. Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother 1985; 16:81-6.
29. 29. Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994; 38:713-8.
30. 30. Walsh TJ, Aoki S, Mechinaud F, et al. Effects of preventive, early and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis 1990; 161: 755-60.
31. 31. Jafari HS, Saez-Llorens X, Grimprel E, Olsen KD, McCracken GH. Characteristics of experimental Candida albicans infection of the central nervous System in rabbits. J Infect Dis 1991; 164:389-95.
32. 32. Jafari HS, Saez-Llorens X, Severien C, et al. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis. Antimicrob Agents Chemother 1994; 38:83-9.
33. 33. Bayer AS, Edwards JE, Seidel JS, Guze LB. Candida meningitis: report of seven cases and review of the English literature. Medicine (Baltimore) 1976; 55:477-86.
34. 34. Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology 1985; 35:1654-7.
35. 35. Odds FC. Candidosis of the central nervous system. In: Odds FC, ed. Candida and candidosis. 2d ed. London: Bailliere Tindall, 1988:187-91.
36. 36. Papastamelos AG, Tunkel AR. Antibacterial agents in infections of the central nervous system and eye. Infect Dis Clin North Am 1995; 9:615-37.
37. 37. Myerowitz RI, Pazin GJ, Allen CM. Disseminated candidiasis. Changes in incidence, underlying disease and pathology. Am J Clin Pathol 1977; 68: 29-38.
38. 38. Lopez-Berestein G, Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Delivery 1984; 1: 199-205.
39. 39. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LSS. Relationships of Pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992; 36:299-307.
40. 40. Valero G, Graybill JR. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob Agents Chemother 1995; 39:2588-90.
41. 41. Leenders ACAP, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome™) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11:1463-71.
42. 42. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35:615-21.
43. 43. Allendoerfer R, Yates RR, Sun SH, Graybill JR. Comparison of amphotericin B lipid complex with amphotericin B and SCH39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992; 30:377-84.
44. 44. Hostetler JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared of those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother 1992; 36:2656-60.
45. 45. Perfect JR, Wright KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994; 33:73-81.
46. 46. Diamond DM, Bauer M, Daniel BE, et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother 1998; 42:528-33.
47. 47. Wang LH, Fielding RM, Smith PC, Guo LSS. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil®) and Fungizone® after repeated dosing in rats. Pharm Res 1995; 12: 275-83.
48. 48. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991; 28(Suppl B): 49-61.
49. 49. Racis SP, Plescia OJ, Geller HM, Schaffner CP. Comparative toxicities of amphotericin B and its monomethyl ester derivative on glial cells in culture. Antimicrob Agents Chemother 1990; 34:1360-5.
50. 50. Walker RW, Rosenblum MK. Amphotericin B associated leukencephalopathy. Neurology 1992; 42:2005-10.
51. 51. Reuhl KR, Vapiwala M, Ryzlak MT, Schaffner CP. Comparative neurotoxicities of amphotericin B and its non-methyl ester derivatives in rats. Antimicrob Agents Chemother 1993; 37:419-28.
52. 52. Mott SH, Packer RJ, Vezina LG, et al. Encephalopathy with parkinsonian features in children following bone marrow transplantation and high dose amphotericin B. Ann Neurol 1995; 37:810-4.
53. 53. Manley TJ, Chusid MJ, Rand SD, Wells D, Margolis DA. Reversible parkinsonism in a child after marrow transplantation and lipid-based amphotericin B therapy. Pediatr Infect Dis J 1998; 17:433-4.
54. 54. Toekes ZA, St. Peteri AK, Todd JA. Availability of liposome content to the central nervous system. Liposomes and the blood-brain barrier. Brain Res 1980; 188:282-6.
55. 55. Micklus MJ, Greig NH, Tung J, Rapoport SI. Organ distribution of liposomal formulations following intracarotid infusion in rats. Biochim Biophys Acta 1992; 1124:7-12.
56. 56. de Lalla F, Pelizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995; 20:263-6.
57. 57. van der Horst C, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337:15-21.
58. 58. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B in 23 patients with AIDS. AIDS 1993, 7:829-35.
59. 59. Hamill RJ, Sobel J, El-Sadr W, et al. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract 1161]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:490.